Estrogens and Prostate Cancer: Etiology, Mediators, Prevention, and Management

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 591-614

  Ho, Shuk Mei ^a,b   Lee, Ming Tsung ^a   Lam, Hung Ming ^a,b   Leung, Yuet Kin ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiestrogens; Chemoprevention; Epigenetics; Estrogen receptor; Hormonal therapy; Phytoestrogen; Prostate cancer risk; Selective estrogen receptor modulator (SERM)

Indexed keywords

2 METHOXYESTRONE; ANTIESTROGEN; AROMATASE INHIBITOR; DIETHYLSTILBESTROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR; ESTRAMUSTINE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR ALPHA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GENISTEIN; LICOCHALCONE A; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOESTROGEN; PLACEBO; RALOXIFENE; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CPG ISLAND; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; ETHNICITY; GENE FREQUENCY; GENE SILENCING; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; GLUCURONIDATION; HORMONE ACTION; HUMAN; MOLECULAR IMPRINTING; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DOMAIN; RACE DIFFERENCE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; UPREGULATION;

ADENOCARCINOMA; ANIMALS; DISEASE SUSCEPTIBILITY; ESTROGENS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 80052249325     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.002     Document Type: Review

References (250)

1. Bostwick D.G., Burke H.B., Djakiew D., et al. Human prostate cancer risk factors. Cancer 2004, 101(Suppl 10):2371-2490.
2. Ho S.M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004, 91(3):491-503.
3. Ho S.M., Leung Y.K., Chung I. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann N Y Acad Sci 2006, 1089:177-193.
4. Abdelrahaman E., Raghavan S., Baker L., et al. Racial difference in circulating sex hormone-binding globulin levels in prepubertal boys. Metabolism 2005, 54(1):91-96.
5. Hui S.L., DiMeglio L.A., Longcope C., et al. Difference in bone mass between black and white American children: attributable to body build, sex hormone levels, or bone turnover?. J Clin Endocrinol Metab 2003, 88(2):642-649.
6. Richards R.J., Svec F., Bao W., et al. Steroid hormones during puberty: racial (black-white) differences in androstenedione and estradiol-the Bogalusa Heart Study. J Clin Endocrinol Metab 1992, 75(2):624-631.
7. Rohrmann S., Nelson W.G., Rifai N., et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007, 92(7):2519-2525.
8. Ross R., Bernstein L., Judd H., et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986, 76(1):45-48.
9. de Jong F.H., Oishi K., Hayes R.B., et al. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res 1991, 51(13):3445-3450.
10. Orwoll E.S., Nielson C.M., Labrie F., et al. Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab 2010, 95(10):E151-E160.
11. Ellem S.J., Risbridger G.P. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010, 118(4-5):246-251.
12. Feldman H.A., Longcope C., Derby C.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87(2):589-598.
13. Gray A., Berlin J.A., McKinlay J.B., et al. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991, 44(7):671-684.
14. Gray A., Feldman H.A., McKinlay J.B., et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991, 73(5):1016-1025.
15. Griffiths K. Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 2000, 45(2):87-100.
16. Roberts R.O., Jacobson D.J., Rhodes T., et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004, 61(2):124-131.
17. Vermeulen A., Rubens R., Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972, 34(4):730-735.
18. Gapstur S.M., Gann P.H., Kopp P., et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev 2002, 11(10 Pt 1):1041-1047.
19. Krieg J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26(6):833-876.
20. Moretti C., Frajese G.V., Guccione L., et al. Androgens and body composition in the aging male. J Endocrinol Invest 2005, 28(Suppl 3):56-64.
21. Starka L., Pospisilova H., Hill M. Free testosterone and free dihydrotestosterone throughout the life span of men. J Steroid Biochem Mol Biol 2009, 116(1-2):118-120.
22. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993, 77(2):375-381.
23. Farnsworth W.E. Roles of estrogen and SHBG in prostate physiology. Prostate 1996, 28(1):17-23.
24. Ellem S.J., Schmitt J.F., Pedersen J.S., et al. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004, 89(5):2434-2441.
25. Ellem S.J., Risbridger G.P. Aromatase and prostate cancer. Minerva Endocrinol 2006, 31(1):1-12.
26. McPherson S.J., Wang H., Jones M.E., et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001, 142(6):2458-2467.
27. Bain J. Testosterone and the aging male: to treat or not to treat?. Maturitas 2010, 66(1):16-22.
28. Prins G.S., Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73(3):233-244.
29. Singh P.B., Matanhelia S.S., Martin F.L. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 2008, 44(7):928-936.
30. Bosland M.C. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999, 35(5-6):459-463.
31. Ho S.M., Lane K., Lee K. Neoplastic transformation of the prostate. Prostate: basic and clinical aspects 1997, 74-114. CRC Press, New York. R.K. Naz (Ed.).
32. Ricke W.A., Wang Y., Cunha G.R. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 2007, 75(9):871-882.
33. Taplin M.E., Ho S.M. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab 2001, 86(8):3467-3477.
34. Adams J.Y., Leav I., Lau K.M., et al. Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. Prostate 2002, 52(1):69-81.
35. Ho S.M., Leav I., Merk F.B., et al. Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. Lab Invest 1995, 73(3):356-365.
36. Leav I., Ho S.M., Ofner P., et al. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 1988, 80(13):1045-1053.
37. Leav I., Merk F.B., Kwan P.W., et al. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989, 15(1):23-40.
38. Yatkin E., Bernoulli J., Talvitie E.M., et al. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 2009, 32(4):399-410.
39. Hsu A., Bruno R.S., Lohr C.V., et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFkappaB pathway in the Noble rat model. J Nutr Biochem 2011, 22(5):502-510.
40. Ricke W.A., Ishii K., Ricke E.A., et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006, 118(9):2123-2131.
41. Kaplan P.J., Leav I., Greenwood J., et al. Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis 1996, 17(12):2571-2579.
42. Wong Y.C., Xie W., Tsao S.W. Structural changes and alteration in expression of TGF-beta1 and its receptors in prostatic intraepithelial neoplasia (PIN) in the ventral prostate of noble rats. Prostate 2000, 45(4):289-298.
43. Wang Y.Z., Wong Y.C. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998, 35(3):165-177.
44. Lau K.M., Leav I., Ho S.M. Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 1998, 139(1):424-427.
45. Leav I., Merk F.B., Lee K.F., et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999, 154(3):863-870.
46. Leav I., Galluzzi C.M., Ziar J., et al. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest 1996, 75(3):361-370.
47. Ling M.T., Wang X., Ouyang X.S., et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 2002, 21(55):8498-8505.
48. Ghatak S., Oliveria P., Kaplan P., et al. Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. Prostate 1996, 29(2):91-100.
49. Ho S.M., Leav I., Ghatak S., et al. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 1998, 153(1):131-139.
50. Ouyang X.S., Wang X., Lee D.T., et al. Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 2001, 22(6):965-973.
51. Ghatak S., Ho S.M. Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats. Biochem Biophys Res Commun 1996, 222(2):362-367.
52. Ho S.M., Roy D. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett 1994, 84(2):155-162.
53. Tam N.N., Ghatak S., Ho S.M. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 2003, 55(1):1-8.
54. Tam N.N., Szeto C.Y., Sartor M.A., et al. Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17beta-estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats. Neoplasia 2008, 10(1):20-40.
55. Thompson C.J., Tam N.N., Joyce J.M., et al. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 2002, 143(6):2093-2105.
56. Chan F.L., Ho S.M. Comparative study of glycoconjugates of the rat prostatic lobes by lectin histochemistry. Prostate 1999, 38(1):1-16.
57. Chan F.L., Choi H.L., Ho S.M. Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and protein blotting. Prostate 2001, 46(1):21-32.
58. Li S.C., Chen G.F., Chan P.S., et al. Altered expression of extracellular matrix and proteinases in Noble rat prostate gland after long-term treatment with sex steroids. Prostate 2001, 49(1):58-71.
59. Bernoulli J., Yatkin E., Konkol Y., et al. Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum. Prostate 2008, 68(12):1296-1306.
60. Tam N.N., Leav I., Ho S.M. Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol 2007, 171(4):1334-1341.
61. Yatkin E., Bernoulli J., Lammintausta R., et al. Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis. J Pharmacol Exp Ther 2008, 327(1):58-67.
62. Bernoulli J., Yatkin E., Laakso A., et al. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 2008, 68(7):728-739.
63. Cavalieri E.L., Rogan E.G. A unified mechanism in the initiation of cancer. Ann N Y Acad Sci 2002, 959:341-354.
64. Cavalieri E., Frenkel K., Liehr J.G., et al. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000, 27:75-93.
65. Yager J.D., Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996, 36:203-232.
66. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000, 27:67-73.
67. Jefcoate C.R., Liehr J.G., Santen R.J., et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000, 27:95-112.
68. Lakhani N.J., Sarkar M.A., Venitz J., et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003, 23(2):165-172.
69. Sato F., Fukuhara H., Basilion J.P. Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia 2005, 7(9):838-846.
70. Reiner T., de Las P.A., Gomez L.A., et al. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett 2009, 276(1):21-31.
71. Ghosh R., Ganapathy M., Alworth W.L., et al. Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2009, 113(1-2):25-35.
72. Nock N.L., Cicek M.S., Li L., et al. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006, 27(9):1842-1848.
73. Acevedo C., Opazo J.L., Huidobro C., et al. Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 2003, 57(2):111-117.
74. Caceres D.D., Iturrieta J., Acevedo C., et al. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions. Eur J Epidemiol 2005, 20(1):79-88.
75. Quinones L.A., Irarrazabal C.E., Rojas C.R., et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl 2006, 8(3):349-355.
76. Silig Y., Pinarbasi H., Gunes S., et al. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest 2006, 24(1):41-45.
77. Sobti R.C., Onsory K., Al-Badran A.I., et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 2006, 25(5):287-294.
78. Suzuki M., Mamun M.R., Hara K., et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol 2005, 48(5):752-759.
79. Tanaka Y., Sasaki M., Shiina H., et al. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(2):238-244.
80. Tang Y.M., Green B.L., Chen G.F., et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000, 10(9):761-766.
81. Leung Y.K., Lau K.M., Mobley J., et al. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 2005, 65(9):3726-3734.
82. Hiramatsu M., Maehara I., Ozaki M., et al. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997, 31(2):118-124.
83. Ito K., Fukabori Y., Shibata Y., et al. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur J Endocrinol 2000, 143(4):543-554.
84. Radlmaier A., Eickenberg H.U., Fletcher M.S., et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 1996, 29(4):199-208.
85. Suzuki K., Okazaki H., Ono Y., et al. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. Prostate 1998, 37(2):70-76.
86. Brodie A., Njar V., Macedo L.F., et al. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol 2009, 27(1):53-63.
87. Djurendic E., Daljev J., Sakac M., et al. Synthesis of some epoxy and/or N-oxy 17-picolyl and 17-picolinylidene-androst-5-ene derivatives and evaluation of their biological activity. Steroids 2008, 73(1):129-138.
88. Kruit W.H., Stoter G., Klijn J.G. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anticancer Drugs 2004, 15(9):843-847.
89. Sanderson T., Renaud M., Scholten D., et al. Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells. Eur J Pharmacol 2008, 593(1-3):92-98.
90. Suzuki K., Nakazato H., Matsui H., et al. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 2003, 23(6D):4941-4946.
91. Suzuki K., Nakazato H., Matsui H., et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 2003, 98(7):1411-1416.
92. Li X., Nokkala E., Yan W., et al. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 2001, 142(6):2435-2442.
93. Rajfer J., Coffey D.S. Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 1978, 16(3):186-190.
94. Arai Y., Suzuki Y., Nishizuka Y. Hyperplastic and metaplastic lesions in the reproductive tract of male rats induced by neonatal treatment with diethylstilbestrol. Virchows Arch A Pathol Anat Histol 1977, 376(1):21-28.
95. Arai Y., Mori T., Suzuki Y., et al. Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. Int Rev Cytol 1983, 84:235-268.
96. Prins G.S. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992, 130(6):3703-3714.
97. Vorherr H., Messer R.H., Vorherr U.F., et al. Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. Biochem Pharmacol 1979, 28(12):1865-1877.
98. McLachlan J.A., Newbold R.R., Bullock B. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 1975, 190(4218):991-992.
99. McLachlan J.A. Prenatal exposure to diethylstilbestrol in mice: toxicological studies. J Toxicol Environ Health 1977, 2(3):527-537.
100. Pylkkanen L., Santti R., Newbold R., et al. Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 1991, 18(2):117-129.
101. Prins G.S., Sklarew R.J., Pertschuk L.P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998, 159(3):641-649.
102. Prins G.S., Birch L., Couse J.F., et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 2001, 61(16):6089-6097.
103. vom Saal F.S., Timms B.G., Montano M.M., et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci U S A 1997, 94(5):2056-2061.
104. Ho S.M., Tang W.Y., Belmonte de F.J., et al. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006, 66(11):5624-5632.
105. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000, 21(3):427-433.
106. Potischman N., Troisi R., Thadhani R., et al. Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol Biomarkers Prev 2005, 14(6):1514-1520.
107. Ekbom A., Hsieh C.C., Lipworth L., et al. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. BMJ 1996, 313(7053):337-341.
108. Ekbom A., Wuu J., Adami H.O., et al. Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol Biomarkers Prev 2000, 9(2):221-223.
109. Schrager S., Potter B.E. Diethylstilbestrol exposure. Am Fam Physician 2004, 69(10):2395-2400.
110. Chapin R.E., Adams J., Boekelheide K., et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol A. Birth Defects Res B Dev Reprod Toxicol 2008, 83(3):157-395.
111. Ikezuki Y., Tsutsumi O., Takai Y., et al. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 2002, 17(11):2839-2841.
112. Kuroda N., Kinoshita Y., Sun Y., et al. Measurement of bisphenol A levels in human blood serum and ascitic fluid by HPLC using a fluorescent labeling reagent. J Pharm Biomed Anal 2003, 30(6):1743-1749.
113. Ranjit N., Siefert K., Padmanabhan V. Bisphenol-A and disparities in birth outcomes: a review and directions for future research. J Perinatol 2010, 30(1):2-9.
114. Schonfelder G., Wittfoht W., Hopp H., et al. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect 2002, 110(11):A703-A707.
115. Tsurusaki T., Aoki D., Kanetake H., et al. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003, 88(3):1333-1340.
116. Yamada H., Furuta I., Kato E.H., et al. Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reprod Toxicol 2002, 16(6):735-739.
117. Braniste V., Jouault A., Gaultier E., et al. Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats. Proc Natl Acad Sci U S A 2010, 107(1):448-453.
118. Prins G.S., Tang W.Y., Belmonte J., et al. Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: epigenetic mode of action is implicated. Fertil Steril 2008, 89(Suppl 2):e41.
119. Rubin B.S., Soto A.M., Bisphenol A. Perinatal exposure and body weight. Mol Cell Endocrinol 2009, 304(1-2):55-62.
120. Badger T.M., Gilchrist J.M., Pivik R.T., et al. The health implications of soy infant formula. Am J Clin Nutr 2009, 89(5):1668S-1672S.
121. Joeckel R.J., Phillips S.K. Overview of infant and pediatric formulas. Nutr Clin Pract 2009, 24(3):356-362.
122. Tuohy P.G. Soy infant formula and phytoestrogens. J Paediatr Child Health 2003, 39(6):401-405.
123. Hamilton-Reeves J.M., Rebello S.A., Thomas W., et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer 2008, 60(1):7-13.
124. Ide H., Tokiwa S., Sakamaki K., et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010, 70(10):1127-1133.
125. Kwan W., Duncan G., Van P.C., et al. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer 2010, 62(2):198-207.
126. Pendleton J.M., Tan W.W., Anai S., et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008, 8:132.
127. Vaishampayan U., Hussain M., Banerjee M., et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007, 59(1):1-7.
128. Risbridger G.P., Ellem S.J., McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 2007, 39(3):183-188.
129. Warner M., Gustafsson J.A. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010, 396(1):63-66.
130. Katzenellenbogen B.S., Sun J., Harrington W.R., et al. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann N Y Acad Sci 2001, 949:6-15.
131. Dondi D., Piccolella M., Biserni A., et al. Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17beta-diol. Endocr Relat Cancer 2010, 17(3):731-742.
132. Leung Y.K., Mak P., Hassan S., et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 2006, 103(35):13162-13167.
133. McPherson S.J., Hussain S., Balanathan P., et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A 2010, 107(7):3123-3128.
134. Osborne C.K., Schiff R., Fuqua S.A., et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001, 7(Suppl 12):4338s-4342s.
135. Tremblay G.B., Giguere V. Coregulators of estrogen receptor action. Crit Rev Eukaryot Gene Expr 2002, 12(1):1-22.
136. Barone I., Brusco L., Fuqua S.A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010, 16(10):2702-2708.
137. Leung Y.K., Lam H.M., Wu S., et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 2010, 17(3):675-689.
138. Fixemer T., Remberger K., Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003, 54(2):79-87.
139. Horvath L.G., Henshall S.M., Lee C.S., et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001, 61(14):5331-5335.
140. Latil A., Bieche I., Vidaud D., et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001, 61(5):1919-1926.
141. Leav I., Lau K.M., Adams J.Y., et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001, 159(1):79-92.
142. Royuela M., de Miguel M.P., Bethencourt F.R., et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001, 168(3):447-454.
143. Torlakovic E., Lilleby W., Torlakovic G., et al. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 2002, 33(6):646-651.
144. Weihua Z., Warner M., Gustafsson J.A. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 2002, 193(1-2):1-5.
145. Pasquali D., Staibano S., Prezioso D., et al. Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol 2001, 178(1-2):47-50.
146. Pasquali D., Rossi V., Esposito D., et al. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 2001, 86(5):2051-2055.
147. Zhu X., Leav I., Leung Y.K., et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004, 164(6):2003-2012.
148. Zhang X., Leung Y.K., Ho S.M. AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene 2007, 26(52):7346-7354.
149. Lai J.S., Brown L.G., True L.D., et al. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004, 64(4):814-820.
150. Mak P., Leav I., Pursell B., et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17(4):319-332.
151. Nanni S., Benvenuti V., Grasselli A., et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009, 119(5):1093-1108.
152. Leung YK, Lee MT, Wang J, et al. Post-transcriptional regulation of estrogen receptor beta isoforms in prostate cancer. In: ENDO 2010 92th Annual Meeting. San Diego (CA), June 19-22, 2010.
153. Lee MT, Leung YK, Chung I, et al. Regulation of ERbeta1 transcriptional activity by acetylation. In: ENDO 2010 92th Annual Meeting. San Diego (CA), June 19-22, 2010.
154. Mak P., Leung Y.K., Tang W.Y., et al. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006, 8(11):896-904.
155. Krege J.H., Hodgin J.B., Couse J.F., et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998, 95(26):15677-15682.
156. Jiang J., Chang H.L., Sugimoto Y., et al. Effects of age on growth and ERbeta mRNA expression of canine prostatic cells. Anticancer Res 2005, 25(6B):4081-4090.
157. Chang W.Y., Prins G.S. Estrogen receptor-beta: implications for the prostate gland. Prostate 1999, 40(2):115-124.
158. Risbridger G.P., Bianco J.J., Ellem S.J., et al. Oestrogens and prostate cancer. Endocr Relat Cancer 2003, 10(2):187-191.
159. Haqq C., Li R., Khodabakhsh D., et al. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 2005, 65(2):101-109.
160. Tanaka Y., Sasaki M., Kaneuchi M., et al. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 2003, 37(4):202-208.
161. Chae Y.K., Huang H.Y., Strickland P., et al. Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One 2009, 4(8):e6523.
162. Nicolaiew N., Cancel-Tassin G., Azzouzi A.R., et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 2009, 160(1):101-106.
163. McIntyre M.H., Kantoff P.W., Stampfer M.J., et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2233-2236.
164. Chen Y.C., Kraft P., Bretsky P., et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2007, 16(10):1973-1981.
165. Hedelin M., Balter K.A., Chang E.T., et al. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 2006, 66(14):1512-1520.
166. Thellenberg-Karlsson C., Lindstrom S., Malmer B., et al. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006, 12(6):1936-1941.
167. Shapiro E., Huang H., Masch R.J., et al. Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J Urol 2005, 174(5):2051-2053.
168. Kampa M., Pelekanou V., Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids 2008, 73(9-10):953-960.
169. Losel R., Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003, 4(1):46-56.
170. Zhalilo L.I., Novominskaia I.M. Fiziol Zh 1976, 22(3):410-412. [in Ukrainian].
171. Hammes S.R., Levin E.R. Extranuclear steroid receptors: nature and actions. Endocr Rev 2007, 28(7):726-741.
172. Zhang Z., Maier B., Santen R.J., et al. Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 2002, 294(5):926-933.
173. Song R.X., Zhang Z., Santen R.J. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab 2005, 16(8):347-353.
174. O'Lone R., Knorr K., Jaffe I.Z., et al. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol 2007, 21(6):1281-1296.
175. Chen J.Q., Russo P.A., Cooke C., et al. ERbeta shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in estrogen-induced synthesis of mitochondrial respiratory chain proteins. Biochim Biophys Acta 2007, 1773(12):1732-1746.
176. Revankar C.M., Cimino D.F., Sklar L.A., et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307(5715):1625-1630.
177. Langer G., Bader B., Meoli L., et al. A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010, 75(8-9):603-610.
178. Thomas P., Dressing G., Pang Y., et al. Progestin, estrogen and androgen G-protein coupled receptors in fish gonads. Steroids 2006, 71(4):310-316.
179. Maggiolini M., Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010, 204(2):105-114.
180. Park I.I., Zhang Q., Liu V., et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology 2009, 150(10):4594-4605.
181. Zhang Z., Duan L., Du X., et al. The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate 2008, 68(5):508-516.
182. Lam HM, Ouyang B, Ho SM. Activation of the G-coupled protein receptor 30 (GPR30) by the non-estrogenic ligand G-1 inhibits prostate cancer cell growth and regulation of its expression via an epigenetic mechanism. In: ENDO 2009 91st Annual Meeting. Washington, DC, June 10-13, 2009.
183. Chan Q.K., Lam H.M., Ng C.F., et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010, 17(9):1511-1523.
184. Cheung C.P., Yu S., Wong K.B., et al. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 2005, 90(3):1830-1844.
185. Giguere V., Yang N., Segui P., et al. Identification of a new class of steroid hormone receptors. Nature 1988, 331(6151):91-94.
186. Chen F., Zhang Q., McDonald T., et al. Identification of two hERR2-related novel nuclear receptors utilizing bioinformatics and inverse PCR. Gene 1999, 228(1-2):101-109.
187. Heard D.J., Norby P.L., Holloway J., et al. Human ERRgamma, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol 2000, 14(3):382-392.
188. Hong H., Yang L., Stallcup M.R. Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J Biol Chem 1999, 274(32):22618-22626.
189. Vanacker J.M., Pettersson K., Gustafsson J.A., et al. Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 1999, 18(15):4270-4279.
190. Xie W., Hong H., Yang N.N., et al. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. Mol Endocrinol 1999, 13(12):2151-2162.
191. Zhang Z., Teng C.T. Estrogen receptor-related receptor alpha 1 interacts with coactivator and constitutively activates the estrogen response elements of the human lactoferrin gene. J Biol Chem 2000, 275(27):20837-20846.
192. Suetsugi M., Su L., Karlsberg K., et al. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res 2003, 1(13):981-991.
193. Coward P., Lee D., Hull M.V., et al. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci U S A 2001, 98(15):8880-8884.
194. Tremblay G.B., Bergeron D., Giguere V. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. Endocrinology 2001, 142(10):4572-4575.
195. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972, 22(4):232-240.
196. Cox R.L., Crawford E.D. Estrogens in the treatment of prostate cancer. J Urol 1995, 154(6):1991-1998.
197. Denis L.J., Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000, 18(1):52-74.
198. Shiau A.K., Barstad D., Loria P.M., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95(7):927-937.
199. Bergan R.C., Reed E., Myers C.E., et al. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999, 5(9):2366-2373.
200. Chadha M.K., Ashraf U., Lawrence D., et al. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 2008, 68(13):1461-1466.
201. Hamilton M., Dahut W., Brawley O., et al. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncol 2003, 42(3):195-201.
202. Lissoni P., Vigano P., Vaghi M., et al. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res 2005, 25(5):3597-3599.
203. Shazer R.L., Jain A., Galkin A.V., et al. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int 2006, 97(4):691-697.
204. Smith M.R., Morton R.A., Barnette K.G., et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010, 184(4):1316-1321.
205. Stein S., Zoltick B., Peacock T., et al. Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am J Clin Oncol 2001, 24(3):283-285.
206. el-Rayes B.F., Hussain M.H. Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther 2002, 2(1):37-47.
207. Dahllof B., Billstrom A., Cabral F., et al. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993, 53(19):4573-4581.
208. Fu Y., Hsieh T.C., Guo J., et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 2004, 322(1):263-270.
209. Kim H.T., Kim B.C., Kim I.Y., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 2002, 277(36):32510-32515.
210. Kumar N.B., Cantor A., Allen K., et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004, 59(2):141-147.
211. Kuwajerwala N., Cifuentes E., Gautam S., et al. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002, 62(9):2488-2492.
212. LaVallee T.M., Zhan X.H., Johnson M.S., et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003, 63(2):468-475.
213. Li Y., Sarkar F.H. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002, 132(12):3623-3631.
214. Liu Y., Kyle E., Lieberman R., et al. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation. Clin Exp Metastasis 2000, 18(3):203-212.
215. Matsukawa Y., Marui N., Sakai T., et al. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993, 53(6):1328-1331.
216. Misra R.R., Hursting S.D., Perkins S.N., et al. Genotoxicity and carcinogenicity studies of soy isoflavones. Int J Toxicol 2002, 21(4):277-285.
217. Mor G., Kohen F., Garcia-Velasco J., et al. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000, 73(5):185-194.
218. Neubauer B.L., Best K.L., Counts D.F., et al. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate 1995, 27(4):220-229.
219. Qadan L.R., Perez-Stable C.M., Anderson C., et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001, 285(5):1259-1266.
220. Rafi M.M., Rosen R.T., Vassil A., et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 2000, 20(4):2653-2658.
221. Schulz P., Bauer H.W., Brade W.P., et al. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells. Cancer Res 1988, 48(10):2867-2870.
222. Shimada K., Nakamura M., Ishida E., et al. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis. Mol Carcinog 2003, 36(3):115-122.
223. Yo Y.T., Shieh G.S., Hsu K.F., et al. Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem 2009, 57(18):8266-8273.
224. Kumar A.P., Garcia G.E., Slaga T.J. 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001, 31(3):111-124.
225. Bland L.B., Garzotto M., DeLoughery T.G., et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005, 103(4):717-723.
226. Langley R.E., Godsland I.F., Kynaston H., et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008, 102(4):442-445.
227. Ockrim J.L., Lalani E.N., Laniado M.E., et al. Transdermal estradiol therapy for advanced prostate cancer-forward to the past?. J Urol 2003, 169(5):1735-1737.
228. Ockrim J.L., Lalani E., Kakkar A.K., et al. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005, 174(2):527-533.
229. Gerber G.S., Zagaja G.P., Ray P.S., et al. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000, 55(1):97-101.
230. Ockrim J.L., Lalani E.N., Banks L.M., et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004, 172(6 Pt 1):2203-2207.
231. Taneja S.S., Smith M.R., Dalton J.T., et al. Toremifene-a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 2006, 15(3):293-305.
232. Denis L., Morton M.S., Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 1999, 35(5-6):377-387.
233. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006, 176(3):965-970.
234. Jian L. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 2009, 53(2):217-226.
235. Lampe J.W. Emerging research on equol and cancer. J Nutr 2010, 140(7):1369S-1372S.
236. Markiewicz L., Garey J., Adlercreutz H., et al. In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 1993, 45(5):399-405.
237. Milligan S.R., Balasubramanian A.V., Kalita J.C. Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environ Health Perspect 1998, 106(1):23-26.
238. Sonn G.A., Aronson W., Litwin M.S. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005, 8(4):304-310.
239. Ganry O. Phytoestrogens and prostate cancer risk. Prev Med 2005, 41(1):1-6.
240. Hebert J.R., Hurley T.G., Olendzki B.C., et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998, 90(21):1637-1647.
241. Hussain M., Banerjee M., Sarkar F.H., et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003, 47(2):111-117.
242. Lee M.M., Gomez S.L., Chang J.S., et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003, 12(7):665-668.
243. Ozasa K., Nakao M., Watanabe Y., et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004, 95(1):65-71.
244. Stattin P., Adlercreutz H., Tenkanen L., et al. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002, 99(1):124-129.
245. Strom S.S., Yamamura Y., Duphorne C.M., et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 1999, 33(1):20-25.
246. Travis R.C., Spencer E.A., Allen N.E., et al. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2009, 100(11):1817-1823.
247. Dalais F.S., Meliala A., Wattanapenpaiboon N., et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004, 64(3):510-515.
248. Jarred R.A., Keikha M., Dowling C., et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002, 11(12):1689-1696.
249. Miltyk W., Craciunescu C.N., Fischer L., et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003, 77(4):875-882.
250. Takimoto C.H., Glover K., Huang X., et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(11 Pt 1):1213-1221.